A
Angela Dispenzieri
Researcher at Mayo Clinic
Publications - 1212
Citations - 72269
Angela Dispenzieri is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Multiple myeloma & Amyloidosis. The author has an hindex of 117, co-authored 1107 publications receiving 60367 citations. Previous affiliations of Angela Dispenzieri include University of Rochester & Kyungpook National University Hospital.
Papers
More filters
Journal ArticleDOI
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma
Lotfi Benboubker,Meletios A. Dimopoulos,Angela Dispenzieri,John Catalano,Andrew Belch,Michele Cavo,Antonello Pinto,Katja Weisel,Heinz Ludwig,Nizar J. Bahlis,Anne Banos,Mourad Tiab,Michel Delforge,Jamie Cavenagh,Catarina Geraldes,Je-Jung Lee,Christine Chen,Albert Oriol,Javier de la Rubia,Lugui Qiu,Darrell White,Daniel Binder,Kenneth C. Anderson,Jean Paul Fermand,Philippe Moreau,Michel Attal,Robert Knight,Guang Chen,Jason Van Oostendorp,Christian Jacques,Annette Ervin-Haynes,Hervé Avet-Loiseau,Cyrille Hulin,Thierry Facon +33 more
TL;DR: Continuous lenalidomide-dexamethasone given until disease progression was associated with a significant improvement in progression-free survival, with an overall survival benefit at the interim analysis, among patients with newly diagnosed multiple myeloma who were ineligible for stem-cell transplantation.
Journal ArticleDOI
Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial
Brian G.M. Durie,Antje Hoering,Muneer H. Abidi,S. Vincent Rajkumar,Joshua Epstein,Stephen P. Kahanic,Mohan C. Thakuri,Frederic J. Reu,Christopher M. Reynolds,Rachael Sexton,Robert Z. Orlowski,Bart Barlogie,Angela Dispenzieri +12 more
TL;DR: This randomised, open-label, phase 3 trial aimed to study whether the addition of bortezomib to lenalidomide and dexamethasone would improve progression-free survival and provide better response rates in patients with previously untreated multiple myeloma who were not planned for immediate autologous stem-cell transplant.
Journal ArticleDOI
Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines
Shaji Kumar,Joseph R. Mikhael,Francis K. Buadi,David Dingli,Angela Dispenzieri,Rafael Fonseca,Morie A. Gertz,Philip R. Greipp,Suzanne R. Hayman,Robert A. Kyle,Martha Q. Lacy,John A. Lust,Craig B. Reeder,Vivek Roy,Stephen J. Russell,Kristen Detweiler Short,A. Keith Stewart,Thomas E. Witzig,Steven R. Zeldenrust,Robert J. Dalton,S. Vincent Rajkumar,P. Leif Bergsagel +21 more
TL;DR: This set of recommendations represents the development of a set of consensus guidelines by a group of experts to manage patients with newly diagnosed disease based on an interpretation of the best available evidence.
Journal ArticleDOI
Clonal competition with alternating dominance in multiple myeloma
Jonathan J Keats,Marta Chesi,Jan B. Egan,Victoria M. Garbitt,Stephen Palmer,Esteban Braggio,Scott Van Wier,Patrick R. Blackburn,Angela Baker,Angela Dispenzieri,Shaji Kumar,S. Vincent Rajkumar,John D. Carpten,Michael T. Barrett,Rafael Fonseca,A. Keith Stewart,P. Leif Bergsagel +16 more
TL;DR: Serial genomic analysis of samples collected at different points during the disease course of 28 patients with multiple myeloma found that the genomes of standard-risk patients show few changes over time, whereas those of cytogenetically high- risk patients show significantly more changes overTime.
Journal ArticleDOI
Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance
S. Vincent Rajkumar,S. Vincent Rajkumar,Robert A. Kyle,Robert A. Kyle,Terry M. Therneau,Terry M. Therneau,L. Joseph Melton,L. Joseph Melton,Arthur R. Bradwell,Arthur R. Bradwell,Raynell J. Clark,Raynell J. Clark,Dirk R. Larson,Dirk R. Larson,Matthew F. Plevak,Matthew F. Plevak,Angela Dispenzieri,Angela Dispenzieri,Jerry A. Katzmann,Jerry A. Katzmann +19 more
TL;DR: Patients with an abnormal serum FLC ratio, non-immunoglobulin G (non-IgG) MGUS, and a high serum M protein level had a risk of progression at 20 years of 58% (high-risk MGUS) versus 37% with any 2 of these risk factors, 21% with one risk factor, and 5% when none of the risk factors were present (low risk).